| Ticker | PTGX |
|---|---|
| ISIN | US74366E1029 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- sp...
El precio actual de Protagonist Therapeutics, Inc. (PTGX) es de 100,00 , con una variación del -2,55%.
Protagonist Therapeutics, Inc. opera en el sector Healthcare, industria Biotechnology.